Researchers at the University of Eastern Finland have identified a functional pathway to ferry creatine derivatives across the blood-brain barrier by utilizing the sodium-dependent multivitamin transporter (SMVT). Published in ACS Chemical Neuroscience, the study establishes an alternative route for restoring brain energy metabolism in patients with Creatine Transporter Deficiency Syndrome (CTDS), a severe genetic disorder where native creatine transport is impaired. By leveraging endogenous nutrient-uptake systems rather than attempting to force compounds through vascular defenses, this delivery mechanism offers a versatile platform for transporting diverse central nervous system therapeutics.
The blood-brain barrier acts as a vigilant gatekeeper composed of tightly packed capillary endothelial cells, preventing roughly 98% of small-molecule drugs from entering the brain parenchyma. Instead of disrupting this delicate barrier, which risks neuroinflammation and systemic toxicity, pharmaceutical neuroscientists are increasingly turning to "Trojan horse" strategies that chemically disguise therapeutic molecules to hitch a ride on natural influx transporters. The University of Eastern Finland team demonstrated that SMVT, which physiologically mediates the uptake of essential water-soluble vitamins like biotin and pantothenic acid, can effectively shuttle synthesized creatine derivatives across cerebral microvessels.
This approach addresses a critical gap in treating CTDS, an X-linked metabolic disorder caused by mutations in the SLC6A8 gene. In affected individuals, the primary creatine transporter fails entirely, leading to profound cerebral creatine depletion and symptoms such as severe intellectual disability, speech delays, early-onset epilepsy, and autistic-like behaviors. Standard dietary creatine supplementation is clinically ineffective because the molecule cannot cross the brain's microvascular endothelium without a functioning native transporter. To circumvent this block, doctoral researchers Adéla Králová and Ville Kuorikoski investigated whether SMVT could recognize engineered creatine conjugates.
Through in vitro and molecular delivery evaluations, the investigators confirmed that modifying creatine into targeted prodrug derivatives enabled SMVT-mediated recognition and transport. This confirms that the brain's multivitamin machinery can serve as a secondary gateway when standard creatine transport channels are compromised. The lead derivative, designated compound 1 (COMP 1), demonstrated SMVT-mediated uptake at concentrations below 100 μM in human glioblastoma cells and mouse neurons, accumulating in the mouse brain and interacting with the creatine kinase system.
Associate Professor Kristiina Huttunen, who led the research team, noted that the most significant outcome is that SMVT proved suitable for delivering different types of compounds into the brain. Because SMVT is stably expressed along the human brain capillary endothelium, conjugating neuroactive molecules to SMVT-recognized chemical motifs provides a reproducible method for enhancing the blood-brain permeability of diverse therapeutic classes, ranging from neuroprotective compounds to anticonvulsants. Supported by a Proof of Concept award from the Jane and Aatos Erkko Foundation, the investigators are advancing these synthesized derivatives into pre-clinical pharmacokinetic evaluations to validate sustained cerebral uptake and functional ATP restoration in vivo.
Sources: Neuroscience News.